Welcome to our dedicated page for Acadia Pharmaceuticals news (Ticker: ACAD), a resource for investors and traders seeking the latest updates and insights on Acadia Pharmaceuticals stock.
Acadia Pharmaceuticals Inc (ACAD) delivers innovative therapies for central nervous system disorders and rare diseases through targeted research and clinical development. This dedicated news hub provides investors and healthcare professionals with essential updates on ACAD's progress in neurology and neuro-rare disease treatments.
Access timely reports on clinical trial milestones, regulatory developments, and strategic partnerships. Our curated collection includes updates on Parkinson's Disease Psychosis therapies, Rett syndrome research advancements, and pipeline progress across ACAD's neuroscience portfolio. Each release maintains scientific rigor while remaining accessible to both medical experts and investment analysts.
Key coverage areas include FDA submissions, peer-reviewed study publications, and collaborative research initiatives. Bookmark this page for centralized access to ACAD's latest scientific achievements and operational updates, carefully vetted for accuracy and relevance to long-term therapeutic development.
Acadia Pharmaceuticals announced a late-breaking oral presentation at the 2022 American Academy of Neurology Annual Meeting in Seattle, WA, highlighting data from the Phase 3 Lavender trial of trofinetide for Rett syndrome. Scheduled for April 5, this pivotal study aims to address the significant unmet needs of patients. Additionally, an e-poster will review the efficacy of pimavanserin in managing psychosis in Parkinson’s disease. Rett syndrome affects approximately 6,000-9,000 patients in the US, underscoring the importance of these findings.
Acadia Pharmaceuticals, listed on NASDAQ as ACAD, will present at the 1st Annual Needham Virtual Neuroscience Forum on March 16, 2022, at 3:20 p.m. ET. A live webcast of the presentation can be accessed through the company’s website, with an archived version available until April 16, 2022.
Acadia is focused on neuroscience advancements, being known for its therapy for hallucinations in Parkinson’s disease psychosis. The company is also developing treatments for dementia-related psychosis and other neuropsychiatric conditions.
Acadia Pharmaceuticals (NASDAQ: ACAD) announced that the FDA has set a target action date of August 4, 2022 for its resubmitted supplemental New Drug Application for pimavanserin, aimed at treating hallucinations and delusions associated with Alzheimer’s disease psychosis. An FDA Advisory Committee meeting is also planned as part of the review process. With around 30% of Alzheimer's patients experiencing psychosis, the approval could address a critical unmet need in this area, enhancing the lives of patients and caregivers.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) will present at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 2:50 p.m. Eastern Time. The conference is virtual, and a live webcast will be available on Acadia’s website, with an archived recording accessible until April 9, 2022.
Acadia focuses on breakthroughs in neuroscience, notably developing the first approved therapy for hallucinations and delusions related to Parkinson’s disease psychosis and is targeting psychosis in dementia, schizophrenia, and Rett syndrome.
Acadia Pharmaceuticals (ACAD) reported a 10% increase in full-year 2021 net sales, totaling $484.1 million, driven by strong NUPLAZID prescription growth. The company has resubmitted its sNDA for pimavanserin targeting Alzheimer's disease psychosis and announced positive results from the Phase 3 Lavender trial for trofinetide in Rett syndrome. Despite a net loss of $167.9 million for 2021, improved cash reserves stand at $520.7 million. Acadia's 2022 guidance includes projected NUPLAZID sales of $510 to $560 million.
Acadia Pharmaceuticals (NASDAQ: ACAD) has resubmitted its supplemental New Drug Application (sNDA) for pimavanserin to the FDA, addressing the issues raised in a Complete Response Letter received in April 2021. The sNDA is aimed at gaining approval for pimavanserin to treat hallucinations and delusions associated with Alzheimer's disease psychosis (ADP). The resubmission includes new analyses from the HARMONY and Study-019 clinical trials, which support the proposed indication. Currently, no FDA-approved treatment exists for ADP.
Acadia Pharmaceuticals will report its fourth quarter and full year 2021 financial results on February 28, 2022, after U.S. market close. A conference call to discuss these results is scheduled for 4:30 p.m. Eastern Time on the same day. Participants can access the call via phone or through a live webcast on Acadia's website, where the session will be archived until March 28, 2022. The company has a strong focus on neuroscience and has developed treatments for Parkinson’s disease psychosis and is working on therapies for dementia-related psychosis and schizophrenia.
Acadia Pharmaceuticals (NASDAQ: ACAD) will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 1:40 p.m. ET. The event will be held virtually, with a live webcast available on Acadia's website under the investors section. An archived recording will be accessible until March 18, 2022. Acadia focuses on neuroscience breakthroughs, having developed the first approved treatment for Parkinson’s disease psychosis and is advancing therapies for dementia-related psychosis and other CNS disorders.
Acadia Pharmaceuticals and Stoke Therapeutics have formed a collaboration to co-develop RNA-based therapies for severe neurodevelopmental diseases, including SYNGAP1 syndrome and Rett syndrome. Acadia gains exclusive licenses for two additional preclinical programs. Stoke receives a $60 million upfront payment, with potential milestone payments reaching $907 million, along with royalties. The partnership combines Stoke’s TANGO research platform with Acadia’s development expertise, aiming to enhance treatment options for patients with these debilitating conditions.
Acadia Pharmaceuticals (Nasdaq: ACAD) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 10:30 a.m. Eastern Time. The event will be held virtually, featuring a live audio-only webcast of Acadia's presentation and Q&A session, which can be accessed on their website and will be available for replay until February 11, 2022.
Acadia focuses on advancing neuroscience breakthroughs, including treatments for psychosis related to Parkinson's disease, dementia, schizophrenia, and Rett syndrome.
FAQ
What is the current stock price of Acadia Pharmaceuticals (ACAD)?
What is the market cap of Acadia Pharmaceuticals (ACAD)?
